On a weekday morning in Dublin, a group of patients walked into a weight-loss clinic hoping to shed pounds. What they didn’t ...

Wegovy (active ingredient semaglutide) and Manjaro (active ingredient tirzepatide), which have created a sensation in the obesity medication market worldwide, are also competing in the obesity ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

You should inject semaglutide subcutaneously, that is, just under the surface of your skin. You can rotate injections between your stomach, upper arm, and thigh. Semaglutide is a prescription type ...

Separate studies had suggested tirzepatide led to more weight loss than semaglutide, which Novo Nordisk sells as Ozempic, for diabetes and, Wegovy, at a higher dose, for weight loss. The new study ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in diabetes control and weight loss. Research has revealed additional ...

Semaglutide could help people drink less alcohol. Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

But how long can you take semaglutide without your weight loss stalling? We asked experts to weigh in on using the medication long-term. How long can you take semaglutide for optimal weight loss?

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.